Search results for "Body"

showing 10 items of 6956 documents

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Immunoglobulin E (IgE) and ischemic heart disease. Which came first, the chicken or the egg?

2014

Several lines of evidence demonstrate that the immune system plays a pivotal role in development and progression of ischemic heart disease (IHD). More recently, a series of biological and clinical investigations has generated new interest about the existence of a relationship between a specific class of immunoglobulin, that is immunoglobulin E (IgE), and IHD. Data obtained in several epidemiological studies have convincingly demonstrated that the concentration of total serum IgEs is significantly increased in patients with IHD and often correlates with the prognosis. The putative mechanisms are essentially mediated by a physiological interaction between IgEs and mast cells, which triggers t…

medicine.medical_treatmentCoronary Vessel AnomaliesMyocardial IschemiaDiseaseImmunoglobulin Eimmunoglobulin EPathogenesisImmune systemMedicineHumanscardiovascular diseasesMyocardial infarctionMast Cellsischemic heart disease; immunoglobulin E; immune systembiologybusiness.industryGeneral MedicineImmunotherapymedicine.diseaseischemic heart diseaseIncreased IgE levelimmune systemImmunologybiology.proteinAntibodybusinessJob Syndrome
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Induction of Type-Specific Neutralizing Antibodies by Capsomeres of Human Papillomavirus Type 33

2001

Abstract The immunogenicity of capsomeres of human papillomavirus type 33 was evaluated in a dose–response analysis. Capsomeres were obtained free of capsids by expression of L1 carrying the single point mutation C427S. Neutralizing antibodies were detected using an in vitro pseudoinfection assay. Capsomeres induced type-specific, neutralizing antibodies in mice even in the absence of adjuvant. The neutralization titers of immune sera raised without adjuvant were 10- to 20-fold lower than those of antisera to virus-like particles, but virtually identical using Freund's adjuvant. These data indicate that capsomeres may substitute for virus-like particles in future vaccines when used with an …

medicine.medical_treatmentDose-Response Relationship ImmunologicEnzyme-Linked Immunosorbent AssayAntibodies ViralpapillomavirusNeutralizationMiceCapsidNeutralization Testsdose responseVirologymedicineAnimalsHumansPapillomaviridaeAntiserumMice Inbred BALB CbiologyImmunogenicityCapsomereVirionneutralizationvaccinationVirologyTiterCapsidbiology.proteincapsomeresImmunizationAntibodyAdjuvantVirology
researchProduct

POLYPHENOLS FROM RED WINE MODULATE IMMUNE RESPONSIVENESS: BIOLOGICAL AND CLINICAL SIGNIFICANCE.

2008

Many studies have been conducted on the effects of red wine polyphenols on certain diseases, primarily, coronary heart disease (CHD) and, in this respect, evidence has been demonstrated that intake of red wine is associated with a reduction of CHD symptomatology. In this framework, the purpose of this review is to illustrate the effects of polyphenols on immune cells from human healthy peripheral blood. Data will show that polyphenols are able to stimulate both innate and adaptive immune responses. In particular, the release of cytokines such as interleukin (IL)-12, interferon (IFN)-gamma, and IL-10 as well as immunoglobulins may be important for host protection in different immune related …

medicine.medical_treatmentImmunoglobulinsCoronary DiseaseWineImmunoglobulin ENitric OxidePeripheral blood mononuclear cellp38 Mitogen-Activated Protein KinasesNitric oxidePOLYPHENOLSIMMUNE SYSTEMCYTOKINESIMMUNOGLOBULINSNITRIC OXIDEATHEROSCLEROSISRED WINEchemistry.chemical_compoundImmune systemPhenolsInterferonDrug DiscoverymedicineAnimalsHumansPharmacologyFlavonoidsSettore MED/04 - Patologia Generalebiologybusiness.industryImmunityfood and beveragesInterleukinPolyphenolsCytokinechemistryImmunologyChronic Diseasebiology.proteinLeukocytes MononuclearCytokinesAntibodybusinessmedicine.drug
researchProduct

Major histocompatibility complex regulation of cytokine production.

1996

This review describes the phenomenon of the major histocompatibility complex (MHC) control of cytokine production both in experimental animals and in humans. H-2 (mouse MHC) regulates which type of cytokine is selectively produced in response to the hapten trinitrophenyl (TNP). T cells from TNP-immune H-2k mice produce interferon-gamma (IFN-gamma), interleukin-2 (IL-2), IL-3, IL-5, tumor necrosis factor-alpha (TNF-alpha), IL-10, and very low levels of IL-4 on reexposure to the specific antigen in vitro. By contrast, T cells from H-2d mice produce IL-3, TNF-alpha, IL-10, and IL-4 but very low levels of IL-2, IL-5 and IFN-gamma. As MHC-congenic matched strains (BALB/k and BALB/c) are used, th…

medicine.medical_treatmentImmunologychemical and pharmacologic phenomenaMajor histocompatibility complexPeripheral blood mononuclear cellMajor Histocompatibility ComplexInterferon-gammaMiceImmune systemAntigenVirologyImmunopathologymedicineAnimalsHumansbiologyTumor Necrosis Factor-alphaInterleukinsH-2 AntigensCell BiologyCytokineImmunologyAntibody Formationbiology.proteinCytokinesTumor necrosis factor alphaHapten
researchProduct

The effect of dietary phosphorus deficiency on the immune responses of European whitefish (Coregonus lavaretus L.)

2003

Low phosphorous (P) feeds in aquaculture are recommended to reduce eutrophication of water systems. However, the feed should be adequate for normal growth and intact immune defence. Influence of low dietary P supply on non-specific and specific immune defence of European whitefish (Coregonus lavaretus) was studied in two trials. For Trial 1, a semi-purified, low-P diet was formulated and supplied with 0, 2.5, 5.0, 7.5, or 10.0 g P kg(-1)to obtain a P gradient of 4.4-14.9 g kg(-1)diet. Diets were fed to four replicate groups of fingerling whitefish for 42 days in a flow-through, freshwater system maintained at 15 degrees C. Fish fed with the P-unsupplemented diet had significantly lower plas…

medicine.medical_treatmentIntraperitoneal injectionAquacultureAquatic ScienceBiologychemistry.chemical_compoundImmune systemAnimal sciencefoodAntigenAquacultureCoregonus lavaretusmedicineAnimalsEnvironmental ChemistryPhosphorus deficiencyfood.dishbusiness.industryBody WeightGeneral MedicineEuropeImmunoglobulin MchemistryImmunoglobulin MAntibody FormationImmunologybiology.proteinPhosphorus DietaryMuramidasegamma-GlobulinsLysozymebusinessSalmonidaeFish & Shellfish Immunology
researchProduct

Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice.

1992

Abstract Cytochrome P450 IID6 is a drug metabolizing enzyme and the major target antigen in LKM-1 antibody positive chronic active hepatitis. The histological hallmark of chronic active hepatitis is a lymphocytic infiltrate in the liver. It is unknown whether and how cytokines produced and secreted by these tissue infiltrating mononuclear cells regulate the cellular expression of cytochrome P450 IID6. To study the effect of interleukin 1, tumor necrosis factor and interleukin 6 on the hepatocellular RNA expression of cytochrome P450 IID, we injected each of the cytokines in C3H HeJ mice. We found a time-dependent suppression of the cytochrome in the liver. Six hours after the intraperitonea…

medicine.medical_treatmentIntraperitoneal injectionBiophysicsBiochemistryMixed Function OxygenasesMiceCytochrome P-450 Enzyme SystemmedicineEscherichia coliAnimalsHumansInterleukin 6Molecular BiologyHepatitisMice Inbred C3HbiologyInterleukin-6Tumor Necrosis Factor-alphaCytochrome P450InterleukinCell Biologymedicine.diseaseBlotting NorthernRecombinant ProteinsEndotoxinsCytokineCytochrome P-450 CYP2D6LiverImmunologybiology.proteinRNATumor necrosis factor alphaFemaleAntibodyInterleukin-1Biochemical and biophysical research communications
researchProduct

Ex vivoevidence for PGE2and LTB4involvement in cutaneous leishmaniasis: relation with infection status and cytokine production

1996

SUMMARYEx vivoculture of spleen cells from BALB/c mice infected with 2 × 106Leishmania major(L.major) promastigotes were cultured with ConcanavalinA (ConA) or leishmanial antigen (L. Ag) and tested for prostaglandin E2(PGE2) and for leukotriene B4(LTB4), in order to study their involvement in the evolution of cutaneous leishmaniasis and the connexion with lymphokine-mediated responses. The data were compared with those obtained in BALB/c mice protected againstL. majorby sublethal irradiation (550 rad; cured mice). In the unprotected BALB/c mice the levels of PGE2that were responsible for the depression of interferon-γ (IFN-γ) and tumour necrosis factor-α (TNFα) Th1-associated cytokines and …

medicine.medical_treatmentLeishmaniasis CutaneousInflammationLeukotriene B4DinoprostoneInterferon-gammaMiceTh2 CellsImmune systemCutaneous leishmaniasismedicineAnimalsLeishmania majorInterferon gammaCells CulturedLeishmania majorMice Inbred BALB CbiologyTumor Necrosis Factor-alphaTh1 Cellsbiology.organism_classificationmedicine.diseaseInfectious DiseasesCytokineImmunologyFemaleAnimal Science and ZoologyParasitologyTumor necrosis factor alphaInterleukin-4medicine.symptomSpleenWhole-Body IrradiationEx vivomedicine.drugParasitology
researchProduct

Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.

2014

Multivalent synthetic vaccines were obtained by solid-phase synthesis of tumor-associated MUC1 glycopeptide antigens and their coupling to a Pam3 Cys lipopeptide through click reactions. These vaccines elicited immune responses in mice without the use of any external adjuvant. The vaccine containing four copies of a MUC1 sialyl-TN antigen showed a significant cluster effect. It induced in mice prevailing IgG2a antibodies, which bind to MCF-7 breast tumor cells and initiate the killing of these tumor cells by activation of the complement-dependent cytotoxicity complex.

medicine.medical_treatmentLipoproteinsEpitopes T-LymphocyteApoptosisCancer VaccinesCatalysisAntibodieschemistry.chemical_compoundMiceImmune systemAntigenmedicineAnimalsHumansAmino Acid Sequenceskin and connective tissue diseasesCytotoxicityMUC1Mice Inbred BALB CbiologyMucin-1GlycopeptidesLipopeptideGeneral ChemistryCombinatorial chemistryGlycopeptidechemistrybiology.proteinCancer researchMCF-7 CellsClick ChemistryRabbitsAntibodyAdjuvantAngewandte Chemie (International ed. in English)
researchProduct